PEspeaks

Oct 08, 2012
Pharmaceutical Executive
With the Supreme Court’s decision in June to uphold the Patient Protection and Affordable Care Act (ACA), life science companies gained access to 32 million potential new customers.
Oct 08, 2012
Pharmaceutical Executive
The call for stiffer FDA regulation of compounded drugs has been reignited by a national fungal meningitis outbreak.
Sep 25, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The sessions focused heavily on the state of doing business in Brazil.
Sep 25, 2012
Pharmaceutical Executive
The furore that burst across Brussels in late September over reported findings of tumors in rats fed with genetically modified maize may seem only tangentially related to the concerns.
Sep 25, 2012
Pharmaceutical Executive
Even though Congress authorized both existing and new user fees for the Food and Drug Administration several months ago through the FDA Safety & Innovation Act (FDASIA).
Sep 21, 2012
Pharmaceutical Executive
A recent decision by the Department of Health (DoH) to introduce a compliance regime for NICE (National Institute for Health and Clinical Excellence) technology.
Sep 18, 2012
Pharmaceutical Executive
Pharm Exec’s 2012 Industry Audit relies on 2011 data to compare performance against 2010.
Sep 17, 2012
Pharmaceutical Executive
Cegedim Relationship Management held its annual conference on trends in the life sciences industry last week.
Sep 17, 2012
Pharmaceutical Executive
Cegedim Relationship Management held its annual conference on trends in the life sciences industry last week.
Sep 13, 2012
Pharmaceutical Executive
The most obvious competitors for Sanofi’s Aubagio, the second oral multiple sclerosis (MS) drug to receive FDA approval, would appear to be Novartis’ Gilenya.
native1_300x100
lorem ipsum